Gilead Sciences, Inc.

GILD

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0000882095

D/E

on the D/E boundary of 370 graded peers in healthcare

rank 290 of 370; percentile 78.3; sampling error 2.5 points; lower is stronger

A B C D E

D/E, the sloth



Scoreboard

Profitability	C percentile 43.4
Solvency	D/E percentile 79.5
Growth and financing	C percentile 53.4
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $59.0B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: short runway, distress
Inputs computable	9 of 14
Graded from	filings received through Feb 24, 2026 247 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$159.24 2026-10-28; market equity $197.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as "Gilead," the "company," "we," "our" or "us") is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 43.4						
Gross profitability	39.3%	32.3%		33.7	369	2025-12-31
Return on invested capital	not computable	9.3%				

latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(2.6%)	(6.6%)	73.6	805	2025-12-31
Gross margin stability, five years	1.4 pts	2.8 pts	22.8	242	2025-12-31
Solvency, sleeve percentile 79.5					
Twelve-month failure probability	not computable	0.07%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	not computable	(0.33)			
one or more required annual facts are missing					
Net debt to EBITDA	not computable	1.82x			
latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	1.55x	2.94x	79.5	832	2025-12-31
Growth and financing, sleeve percentile 53.4					
Revenue growth, three-year compound	2.6%	10.1%	65.0	413	2025-12-31
Free cash flow growth, three-year compound	4.3%	10.9%	62.1	96	2025-12-31
Reinvestment rate	(5.1%)	37.1%	71.8	104	2025-12-31
Asset growth, three years	(2.2%)	2.1%	57.2	697	2025-12-31
Net share issuance, one year	(0.3%)	2.5%	10.8	633	2026-02-13

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
285	Quest Diagnostics Inc. (DGX)	77.0	D	
286	biote Corp. (BTMD)	77.2	D	
287	Protalix BioTherapeutics, Inc. (PLX)	77.5	D/E	
288	Femasys Inc. (FEMY)	77.8	D/E	dilution, short runway
289	Milestone Scientific Inc. (MLSS)	78.0	D/E	late filer
290	Gilead Sciences, Inc. (GILD)	78.3	D/E	
291	X4 Pharmaceuticals, Inc. (XFOR)	78.6	D/E	dilution, fortress balance sheet
292	Ironwood Pharmaceuticals Inc. (IRWD)	78.9	D/E	late filer, fortress balance sheet
293	Whitehawk Therapeutics, Inc. (WHWK)	79.1	D/E	
294	Champions Oncology, Inc. (CSBR)	79.4	D/E	
295	Voyager Therapeutics, Inc. (VYGR)	79.7	D/E	short runway

What the price implies

at the 2026-10-28 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	33.6%	7.7%	68
Distance from 52-week high	0.0%	(27.7%)	95
EBIT to enterprise value	4.6%	(1.5%)	77
Free cash flow yield	4.8%	(1.0%)	82
Book value to price	0.06	0.27	21

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.15	0.31	34
Composite equity issuance, five years	(21.8%)	20.5%	7
Relative strength against the sector, log excess return	0.08	(0.14)	68

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 8 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	84 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$822.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$29.4B	2025-12-31	2026-02-24	10-K	26-000006
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$6.2B	2025-12-31	2026-02-24	10-K	26-000006
3	assets	us-gaap:Assets	$59.0B	2025-12-31	2026-02-24	10-K	26-000006
4	operating income	us-gaap:OperatingIncomeLoss	$7.3B	2022-12-31	2025-02-28	10-K	25-000006
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$5.8B	2022-12-31	2025-02-28	10-K	25-000006
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.2B	2022-12-31	2025-02-28	10-K	25-000006
7	total debt	us-gaap:LongTermDebt	$25.2B	2022-12-31	2024-02-23	10-K	24-000007
8	book equity	us-gaap:StockholdersEquity	$21.2B	2022-12-31	2024-02-23	10-K	24-000007
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$5.4B	2022-12-31	2023-02-22	10-K	23-000007
10	total debt	us-gaap:LongTermDebt	$26.7B	2021-12-31	2023-02-22	10-K	23-000007
11	book equity	us-gaap:StockholdersEquity	$21.1B	2021-12-31	2023-02-22	10-K	23-000007
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$5.3B	2021-12-31	2023-02-22	10-K	23-000007
13	net income	us-gaap:NetIncomeLoss	$8.5B	2025-12-31	2026-02-24	10-K	26-000006
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$10.0B	2025-12-31	2026-02-24	10-K	26-000006
15	assets	us-gaap:Assets	$59.0B	2024-12-31	2026-02-24	10-K	26-000006
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$28.8B	2024-12-31	2026-02-24	10-K	26-000006
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$6.3B	2024-12-31	2026-02-24	10-K	26-000006
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$27.1B	2023-12-31	2026-02-24	10-K	26-000006
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$6.5B	2023-12-31	2026-02-24	10-K	26-000006
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$27.3B	2022-12-31	2025-02-28	10-K	25-000006
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$5.7B	2022-12-31	2025-02-28	10-K	25-000006
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$27.3B	2021-12-31	2024-02-23	10-K	24-000007
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$6.6B	2021-12-31	2024-02-23	10-K	24-000007
24	depreciation amortization	us-gaap:Depreciation	$323.0M	2022-12-31	2025-02-28	10-K	25-000006
25	operating income	us-gaap:OperatingIncomeLoss	$7.6B	2023-12-31	2026-02-24	10-K	26-000006
26	interest expense	us-gaap:InterestExpense	$944.0M	2023-12-31	2024-02-23	10-K	24-000007
27	current assets	us-gaap:AssetsCurrent	$18.3B	2025-12-31	2026-02-24	10-K	26-000006

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	current liabilities	us-gaap:LiabilitiesCurrent	$11.8B	2025-12-31	2026-02-24	10-K	26-000006
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$563.0M	2025-12-31	2026-02-24	10-K	26-000006
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$10.8B	2024-12-31	2026-02-24	10-K	26-000006
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$523.0M	2024-12-31	2026-02-24	10-K	26-000006
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$8.0B	2023-12-31	2026-02-24	10-K	26-000006
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$585.0M	2023-12-31	2026-02-24	10-K	26-000006
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$9.1B	2022-12-31	2025-02-28	10-K	25-000006
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$728.0M	2022-12-31	2025-02-28	10-K	25-000006
36	depreciation amortization	us-gaap:Depreciation	$370.0M	2025-12-31	2026-02-24	10-K	26-000006
37	operating income	us-gaap:OperatingIncomeLoss	$10.0B	2025-12-31	2026-02-24	10-K	26-000006
38	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$9.8B	2025-12-31	2026-02-24	10-K	26-000006
39	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.3B	2025-12-31	2026-02-24	10-K	26-000006
40	current assets	us-gaap:AssetsCurrent	$19.2B	2024-12-31	2026-02-24	10-K	26-000006
41	current liabilities	us-gaap:LiabilitiesCurrent	$12.0B	2024-12-31	2026-02-24	10-K	26-000006
42	assets	us-gaap:Assets	$62.1B	2023-12-31	2025-02-28	10-K	25-000006
43	assets	us-gaap:Assets	$63.2B	2022-12-31	2024-02-23	10-K	24-000007
44	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,241,420,528	2026-02-13	2026-02-24	10-K	26-000006
45	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,245,346,062	2025-02-21	2025-02-28	10-K	25-000006

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.